Primary and secondary endpoints at 12 months in Supreme drug-eluting stent (DES) and durable polymer everolimus-eluting stent (DP-EES) in both acute coronary syndromes (ACS) and chronic coronary syndromes (CCS) presentation. ID-TLR, ischemia-driven target lesion revascularization; MACE, major adverse cardiac events; MI, myocardial infarction; ST, stent thrombosis; TLF, target lesion failure.